期刊
ERJ OPEN RESEARCH
卷 5, 期 1, 页码 -出版社
EUROPEAN RESPIRATORY SOC JOURNALS LTD
DOI: 10.1183/23120541.00073-2018
关键词
-
资金
- European Commission [018996]
- Asthma Foundation of Victoria, Allen and Hanburys
- Belgian Science Policy Office, National Fund for Scientific Research
- Estonian Science Foundation [1088]
- Glaxo France
- Contrat de Plan Etat-Region Languedoc-Rousillon, CNMATS
- CNMRT [90MR/10, 91AF/6]
- Ministre delegue de la sante, RNSP, France
- Bundesminister fur Forschung und Technologie
- Greek Secretary General of Research and Technology, Fisons
- Boehringer Ingelheim
- Ministero dell'Universita e della Ricerca Scientifica e Tecnologica, CNR [RSF 381/05.93]
- Netherlands: Dutch Ministry of Wellbeing, Public Health and Culture and the Netherlands Asthma Foundation
- Norwegian Research Council [214123]
- Glaxo Farmaceutica Lda, Sandoz Portugesa
- Fondo de Investigacion Sanitaria
- (Consejeria de Sanidad del Principado de Asturias) [1997 SGR 00079]
- Servicio Andaluz de Salud
- Swedish Medical Research Council
- Swedish Heart Lung Foundation
- Swedish Association against Asthma and Allergy
- Swiss National Science Foundation [33CSCO-134276/1, 33CSCO-108796, 3247BO-104283, 3247BO-104288, 3247BO-104284, 3247-065896, 3100-059302, 3200-052720, 3200-042532, 4026-028099]
- UK: National Asthma Campaign
- British Lung Foundation
- Dept of Health, South Thames Regional Health Authority
- National Health and Medical Research Council
- Fund for Scientific Research [G.0402.00]
- Flemish Health Ministry
- Tartu Estonian Science Foundation [4350]
- Programme Hospitalier de Recherche Clinique-Direction de la Recherche Clinique (DRC) de Grenoble [2610]
- Direction Generale de la Sante
- Direction Regionale des Affaires Sanitaires et Sociales Languedoc-Roussillon
- Aventis
- GSF-National Research Centre for Environment and Health, Deutsche Forschungsgemeinschaft [MA 711/4-1]
- Icelandic Research Council, Icelandic University Hospital Fund
- Italian Ministry of University and Scientific and Technological Research (MURST), Local University Funding for Research [1998, 1999]
- Turin: Azienda Sanitaria Locale 4 Regione Piemonte (Italy), Azienda Ospedaliera Centro Traumatologico Ospedaliero/Centro Traumatologico Ortopedico-Istituto Clinico Ortopedico Regina Maria Adelaide Regione Piemonte
- Ministero dell'Universita e della Ricerca Scientifica (MURST)
- Glaxo Wellcome SpA
- Norwegian Asthma and Allergy Association
- Glaxo Wellcome AS, Norway Research Fund
- Fondo de Investigacion Santarias [97/0035-01, 99/0034-01, 99/0034 02]
- Hospital Universitario de Albacete, Consejeria de Sanidad
- Fondo de Investigaciones Santarias [97/0035-01, 99/0034-01, 99/0034-02]
- Consell Interdepartamental de Recerca i Innovacio Tecnologica [1999SGR 00241]
- Instituto de Salud Carlos III: Red de Centros de Epidemiologia y Salud Publica [C03/09]
- Red de Bases moleculares y fisiologicas de las Enfermedades Respiratorias [C03/011, G03/176]
- Basque Health Dept Oviedo: Fondo de Investigaciones Sanitaria [99/0034-01, 97/0035-02, 97/0035, 99/0034-04, 99/0034-06, 99/350, 99/0034-07]
- Generalitat de Catalunya [97/0035-01, 99/0034-01, 99/0034-02, C03/09, C03/011, G03/176, CIRIT 1999 SGR 00214, SEPAR R01 HL62633-01]
- Swedish Foundation for Health Care Sciences and Allergy Research
- Swedish Asthma and Allergy Foundation
- Swedish Cancer and Allergy Foundation
- Swedish Council for Working Life and Social Research (FAS)
- Swiss Federal Office for Education and Science, Swiss National Accident Insurance Fund
- UK: Asthma UK
- Medical Research Council [92091]
- Research Foundation Flanders (FWO) [SF0180060s09]
- Estonian Ministry of Education
- Ministere de la Sante
- Programme Hospitalier de Recherche Clinique (PHRC)
- Paris: Agence Nationale de la Sante
- Region Ile de France
- Germany: Erfurt: German Research Foundation [HE 3294/10-1]
- German Research Foundation [MA 711/6-1, 262/7-1]
- Landspitali University Hospital Research Fund, University of Iceland Research Fund
- ResMed Foundation (CA, USA)
- Vegageroin (The Icelandic Road Administration) - Cariverona Foundation, Education Ministry (MIUR)
- Western Norway Regional Health Authorities [911631]
- Bergen Medical Research Foundation
- Sociedad Espanola de Neumologia y Cirurgia Toracica [SEPAR 1001/2010]
- Barcelona: Fondo de Investigacion Sanitaria [PS09/00716]
- Galdakao: Fondo de Investigacion Sanitaria [09/01511]
- Huelva: Fondo de Investigacion Sanitaria [PS09/02185, PS09/03190]
- Swedish Heart and Lung Foundation
- Swedish Asthma and Allergy Association
- Swedish Association against Lung and Heart Disease
- Swedish Research Council for Health, Working Life and Welfare (FORTE)
- Swedish Council for Working Life and Social Research
- Umea: Vasterbotten Country Council ALF grant
- Federal Office for Forest
- Federal Office of Roads and Transport, the Canton's Government of Aargan, Basel-Stadt, Basel-Land, Geneva, Luzern, Ticino, Valais and Zurich
- Swiss Lung League
- Canton's Lung League of Basel-Stadt/Basel, Landschaft, Geneva, Ticino, Valais and Zurich
- Freiwillige Akademische Gesellschaft
- UBS Wealth Foundation
- Talecris Biotherapeutics GmbH
- Abbott Diagnostics
- Wellcome Trust [WT 084703MA]
- UK: Medical Research Council [92091]
- National Institute for Health Research through the Primary Care Research Network
- MRC [G0901214] Funding Source: UKRI
Asthma often remains uncontrolled, despite the fact that the pharmacological treatment has undergone large changes. We studied changes in the treatment of asthma over a 20-year period and identified factors associated with the regular use of inhaled corticosteroid (ICS) treatment. Changes in the use of medication were determined in 4617 randomly selected subjects, while changes in adults with persistent asthma were analysed in 369 participants. The study compares data from three surveys in 24 centres in 11 countries. The use of ICSs increased from 1.7% to 5.9% in the general population and the regular use of ICSs increased from 19% to 34% among persistent asthmatic subjects. The proportion of asthmatic subjects reporting asthma attacks in the last 12 months decreased, while the proportion that had seen a doctor in the last 12 months remained unchanged (42%). Subjects with asthma who had experienced attacks or had seen a doctor were more likely to use ICSs on a regular basis. Although ICS use has increased, only one-third of subjects with persistent asthma take ICSs on a regular basis. Less than half had seen a doctor during the last year. This indicates that underuse of ICSs and lack of regular healthcare contacts remains a problem in the management of asthma.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据